In the preceding three months, 7 analysts have released ratings for Certara (NASDAQ:CERT), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 5 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $11.14, a high estimate of $13.00, and a low estimate of $8.00. This current average represents a 15.41% decrease from the previous average price target of $13.17.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Certara among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Luke Sergott | Barclays | Maintains | Equal-Weight | $8.00 | $8.00 |
| Luke Sergott | Barclays | Lowers | Overweight | $8.00 | $13.00 |
| Scott Schoenhaus | Keybanc | Lowers | Overweight | $12.00 | $13.00 |
| Michael Cherny | Leerink Partners | Announces | Outperform | $13.00 | - |
| Sean Laaman | Morgan Stanley | Lowers | Equal-Weight | $12.00 | $16.00 |
| Luke Sergott | Barclays | Lowers | Overweight | $13.00 | $14.00 |
| Jeff Garro | Stephens & Co. | Lowers | Overweight | $12.00 | $15.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Certara. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Certara compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Certara's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Certara's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Certara analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering Certara: A Closer Look
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
Financial Milestones: Certara's Journey
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Certara displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 10.33%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 1.46%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Certara's ROE stands out, surpassing industry averages. With an impressive ROE of 0.14%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.1%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.28.
Analyst Ratings: What Are They?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Login to comment